About mirdametinib
MEK inhibitor
Used for
- Treatment of adults and children with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
Usual adult dose
Adults: 2 mg by mouth twice daily for 21 days, then 7 days off, in 28-day cycles.
Usual dose in children
Children aged 2 years and older: 2 mg/m² by mouth twice daily for 21 days, then 7 days off, in 28-day cycles; maximum 4 mg twice daily.
Common side effects
- Rash and acne-like skin reactions
- Diarrhea, nausea, or vomiting
- Muscle pain or weakness
- Swelling around the eyes or other fluid retention
Important warnings
- Can cause heart problems; heart function monitoring is required.
- Can damage the eyes, including retinal disorders; eye monitoring is required.
- Can cause severe skin reactions and muscle problems.
- Can harm an unborn baby; effective contraception is required during treatment and afterward.
Pregnancy
May cause fetal harm. Avoid during pregnancy; follow product guidance on contraception during treatment and for one month afterward.
Breastfeeding
Do not breastfeed during treatment and for one month after the final dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase mirdametinib exposure.
- Strong or moderate CYP3A inducers can reduce mirdametinib exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.